

# CONTENTS

<i>Extended contents</i>	vii
<i>List of figures</i>	xv
<i>List of tables</i>	xvi
<i>List of contributors</i>	xvii
<i>Table of cases</i>	xix
<i>Table of legislation</i>	xxxviii
1 Competition law and pharma: an economic perspective <i>Benoît Durand</i>	1
2 Reverse payments: an EU and US perspective <i>Frank Maier-Rigaud, Nathan Blalock and Oliver Gannon</i>	35
3 Article 101 TFEU: horizontal cooperation agreements in the pharmaceutical sector <i>Soledad Blanco Thomas, Lilia Luchianov and Thomas Weck</i>	109
4 The competitive assessment of IP licensing agreements in the pharmaceutical sector <i>Pierre Moullet</i>	175
5 Article 102 TFEU: patent filings as an abuse of dominant position after <i>AstraZeneca</i> : the patent–antitrust interface under a new perspective <i>Francisco Hernández</i>	219
6 Mergers in the pharmaceutical sector <i>Pablo Figueroa and Alejandro Guerrero</i>	247
7 Mergers in the medical devices sector <i>Jan Heithecker</i>	269
8 Antitrust practices in pharmaceutical public procurement <i>Antonio Miño López</i>	311
9 EU trade law and pharmaceuticals <i>Pascale Hecker</i>	377
10 The pharmaceutical sector and parallel trade <i>Eduarne Navarro Varona and Cristina Caballero Candelario</i>	405
11 Free movement and competition in the European market for pharmaceuticals <i>Pedro Caro de Sousa</i>	431
12 IP law and pharmaceuticals: patents and supplementary protection certificates in the pharmaceutical sector <i>Rais Amils</i>	459
13 The EU regulatory framework for medicinal products for human use <i>Marc Martens and Nicolas Carbonnelle</i>	503
14 Antitrust and the pharmaceutical industry in the United States <i>George A. Hay</i>	552

## CONTENTS

---

15	UK competition and trade in the pharma sector <i>Paula Riedel</i>	578
16	Competition law and pharma: China <i>Andrew L. Foster</i>	615
17	Competition law and pharma: Spain <i>Helmut Brokelmann and Mariarosaria Ganino</i>	657
18	The application of competition law in the pharmaceutical sector: challenges for BRICS <i>Maria Ioannidou and Ioannis Kokkoris</i>	687
19	Product hopping: the US approach <i>Michael A. Carrier</i>	716
20	Marketing data in the pharmaceutical sector: a competition law consideration <i>Pedro Callol</i>	733
	<i>Index</i>	761